MONROVIA, Calif. & HOUSTON --(BUSINESS WIRE)--Jan. 6, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced

Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Monrovia, Calif. – December 2, 2010 – Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208),

MONROVIA, Calif. , Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has entered into a

Monrovia, CA – March 2, 2009. Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies.

PDL licenses Xencor XmAb™ technology to enhance antibody activity

Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration Monrovia, CA – January 4, 2005 – Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced an extension to its research collaboration with Roche to create monoclonal antibodies with

— Collaboration joins together Xencor's modular XmAb engineered protein platforms with UCLA's expertise in biology to rapidly create and advance potential new medicines — MONROVIA, Calif. & LOS ANGELES --(BUSINESS WIRE)--Feb. 25, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical

MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 25, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology license agreement with Vir

MONROVIA, Calif. , Jan. 5, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the company's 2018 priorities and

Dahiyat launched Xencor’s biotherapeutic programs and protein design platform